D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity

Synapse

Volumn 50, Issue 1, 2003, Pages 7-13

  Muralikrishnan, Dhanasekharan ^a   Samantaray, Supriti ^a   Mohanakumar, Kochupurackal P ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Antioxidant action; Hydroxyl radicals; L deprenyl; Monoamine oxidase inhibition; MPTP neurotoxicity; Parkinson's disease; Striatal MPP+; Striataldopamine

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; FERROUS CITRATE FE 59; SALICYLATE SODIUM; SELEGILINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ELECTROCHEMICAL ANALYSIS; FENTON REACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; SCAVENGING SYSTEM; STRUCTURE ACTIVITY RELATION; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROXYL RADICAL; ISOMERISM; MICE; MICE, INBRED BALB C; MONOAMINE OXIDASE; NEOSTRIATUM; NEURAL PATHWAYS; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; PARKINSONIAN DISORDERS; SELEGILINE; SUBSTANTIA NIGRA;

EID: 0041920820     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.10239     Document Type: Article

References (58)

1. Adams Jr JD, Odunze IN. 1991. Biochemical mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Could oxidative stress be involved in the brain? Biochem Pharmacol 41:1099-1105.
2. Aubin N, Curet O, Deffois A, Carter C. 1998. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 71:1635-1642.
3. Ballabriga J, Pellise A, Ferrer I. 1997. L-Deprenyl does not reduce brain damage in global forebrain ischemia in adult gerbils (Meriones ungiculatus). J Neurol Sci 148:1-5.
4. Birks J, Flicker L. Selegiline for Alzheimer's disease. 2003. Cochrane Database Syst Rev 1: CD000442
5. Castagnoli K, Palmer S, Anderson A, Bueters T, Castagnoli N, Jr. 1997. The neuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase-B-catalyzed oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Chem Res Toxicol 10:364-368.
6. Chiba K, Trevor A, Castagnoli N, Jr. 1984. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commn 120:574-578.
7. Chiueh CC, Miyake H, Peng MT. 1993. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlining mechanisms involved in MPTP-induced parkinsonism. Adv Neurol 60:251-258.
8. Cohen G, Spina MB. 1989. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 26:689-690.
9. Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD. 1984. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 106:209-210.
10. de la Cruz CP, Revilla E, Steffen V, Rodriguez-Gomez JA, Cano J, Machado A. 1996. Protection of the aged substantia nigra of the rat against oxidative damage by L-deprenyl. Br J Pharmacol 117:1756-1760.
11. Fang J, Yu PH. 1994. Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake. Neuropharmacology 33:763-768.
12. Freedman M, Rewilak D, Xerri T, Cohen S, Gordon AS, Shandling M, Logan AG. 1998. L-deprenyl in Alzheimer's disease: cognitive and behavioural effects. Neurology 50:660-668.
13. + incorporation into cerebellar granule cells. Brain Res Bull 56:119-123.
14. Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P. 2002. Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J Pharmacol Exp Ther 303:952-958.
15. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. 1984. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311:467-469.
16. Iwasaki Y, Ikeda K, Shiojima T, Kobayashi T, Tagaya N, Kinoshita M. 1996. Deprenyl and pergolide rescue spinal motor neurones from axotomy-induced neuronal death in the neonatal rat. Neurol Res 18:168-170.
17. Johnson SK, Medina D, Wagner GC. 1992. The effects of deprenyl on methamphetamine-induced dopamine depletion. J Neural Transm 89:123-127.
18. Knoll J. 1998. (-) Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacol Toxicol 82:57-66.
19. Lahtinen H, Koistinaho J, Kauppinen R, Haapalinna A, Keinanen R, Sivenius J. 1997. Selegiline treatment after transient global ischemia in gerbils enhances the survival of CA1 pyramidal cells in the hippocampus. Brain Res 757:260-267.
20. +)-induced apoptosis independent of MAO-B inhibition. Neurosci Lett 224:197-200.
21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
22. Magyar K, Szende B, Lengyel J, Tekes K. 1996. The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research. J Neural Transm Suppl. 48:29-43.
23. Mitra N, Mohanakumar KP, Ganguly DK. 1994. Resistance of golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship with low levels of regional monoamine oxidase-B. J Neurochem 62:1906-1912.
24. Mohanakumar KP, Muralikrishnan D. 2000. Neurochemical mechanism underlying neuroprotective actions of D- & L-deprenyl, bromocriptine and sodium salicylate in neurodegeneration caused by MPTP in Balb/c mice. In: Collins MA, Storch A, editors. Neurotoxic factors in Parkinson's disease and related disorders. New York: Kluwer Academic/Plenum Press. p 289-294.
25. Mohanakumar KP, de Bartolomeis A, Wu RM, Yeh KJ, Sternberger LM, Peng SY, Murphy DL, Chiueh CC. 1994. Ferrous-citrate complex and nigral degeneration: evidence for free radical formation and lipid peroxidation. Ann NY Acad Sci 738:392-399.
26. Mohanakumar KP, Hanbauer I, Chiueh CC. 1998. Neuroprotection by nitric oxide against hydroxyl radical-induced nigral neurotoxicity. J Chem Neuroanat 14:195-205.
27. Mohanakumar KP, Muralikrishnan D, Thomas B. 2000. Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Brain Res 864:281-290.
28. Mohanakumar KP, Sharma SM, Thomas B, Chowdhury R, Chiueh, CC. 2002. Nitric oxide: an antioxidant and neuroprotector. Ann NY Acad Sci 962:389-401.
29. Morinan A, Garratt HM. 1985. An improved fluorimetric assay for brain monoamine oxidase. J Pharmacol Methods 13:213-223.
30. Munirathinam S, Lakshmana MK, Raju TR. 1996. (-) Deprenyl attenuates aluminium-induced neurotoxicity in primary cortical cultures. Neurodegeneration 5:161-167.
31. Muralikrishnan D, Mohanakumar KP. 1998. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 12:905-912.
32. Mytilineou C, Radcliffe P, Leonardi EK, Werner P, Olanow CW. 1997. L-deprenyl protects mesencephalic dopamine neurones from glutamate receptor-mediated toxicity in vitro. J Neurochem 68:33-39.
33. Mytilineou C, Leonardi EK, Radcliffe P, Heinonen EH, Han SK, Werner P, Cohen G, Olanow CW. 1998. Deprenyl and desmethyl-selegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. J Pharmacol Exp Ther 284:700-706.
34. Olanow CW, Tatton WG. 1999. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 22:123-144.
35. Riva MA, Molteni R, Racagni G. 1997. L-deprenyl potentiates cAMP-induced elevation of FGF-2 mRNA levels in rat cortical astrocytes. Neuroreport 8:2165-2168.
36. Rodriguez-Gomez JA, Venero JL, Vizuete ML, Cano J, Machado A. 1997. Deprenyl induces the tyrosine hydroxylase enzyme in the rat dopaminergic nigrostriatal system. Mol Brain Res 46:31-38.
37. Rothblat DS, Schneider JS. 1998. The effects of L-deprenyl treatment, alone and combined with GM1 ganglioside, on striatal dopamine content and substantia nigra pars compacta neurones. Brain Res 779:226-230.
38. Sairam K, Saravanan KS, Banerjee R, Mohanakumar KP. 2003. Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res 966:245-252.
39. Tatton WG, Greenwood CE. 1991. Rescue of dying neurones: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 30:666-672.
40. Tekes K, Magyar K. 2000. Effect of MAO inhibitors on the high-affinity reuptake of biogenic amines in rat subcortical regions. Neurobiology 8:257-264
41. Tetrud JW, Langston JW. 1989. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 245:519-522.
42. Thiffault C, Aumont N, Quinon R, Poirier J. 1995. Effect of MPTP and L-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain. J Neurochem 65:2725-2733.
43. Thiffault C, Lamarre-Theroux L, Quinon R, Poirier J. 1997. L-deprenyl and MDL 72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse. Mol Brain Res 44:238-244.
44. Thomas CE, Huber EW, Ohlweiler DF. 1997. Hydroxyl and peroxyl radical trapping by the monoamine oxidase-B inhibitors deprenyl and MDL 72,974A: implications for protection of biological substrates. Free Radic Biol Med 22:733-737.
45. Thomas B, Muralikrishnan D, Mohanakumar KP. 2000. In vivo hydroxyl radical generation in the striatum following systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain Res 852:221-224.
46. Thyagarajan S, Felten SY, Felten DL. 1998. Restoration of sympathetic noradrenergic nerve fibres in the spleen by low doses of L-deprenyl treatment in young sympathectomized and old Fischer 344 rats. J Neuroimmunol. 81:144-157.
47. Todd KG, Butterworth RF. 1998. Increased neuronal cell survival after L-deprenyl treatment in experimental thiamine deficiency. J Neurosci Res 52:240-146.
48. Vaglini F, Pardini C, Cavalletti M, Maggio R, Corsini GU. 1996. L-deprenyl fails to protect mesencephalic dopamine neurones and PC12 cells from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion. Brain. Res 741:68-74.
49. Van Kampen JM, McGeer EG, Stoessl AJ. 2000. Dopamine transporter function assessed by antisense knockdown in the rat: protection from dopamine neurotoxicity. Synapse 37:171-178.
50. Wadia JS, Chalmers-Redman RME, Ju WJH, Carlile GW, Phillips JL, Fraser AD, Tatton WG. 1998. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-)-deprenyl. J Neurosci 18:932-947.
51. + in vivo. Eur J Pharmacol 243:241-247.
52. + toxicity by deprenyl (selegiline). Ann NY Acad Sci 738:214-221.
53. Wu RM, Murphy DL, Chiueh CC. 1996. Suppression of hydroxyl radical formation and protection of nigral neurones by 1-deprenyl (selegiline). Ann NY Acad Sci 786:379-390.
54. Youdim MB, Riederer P. 1993. The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease. Mov Disord 8: S8-S13.
55. Youdim MB, Wadia A, Tatton W, Weinstock M. 2001. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann NY Acad Sci 939:450-458.
56. Zang LY, Misra HP. 1993. Generation of reactive oxygen species during the monoamine-catalysed oxidation of the neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Biol Chem 268:16504-16512.
57. Zhang X, Zuo DM, Davis BA, Boulton AA, Yu PH. 1996. Immunohistochemical evidence of neuroprotection by R(-)-deprenyl and N-(2-hexyl)-N-methylpropargylamine on DSP-4-induced degeneration of rat brain noradrenergic axons and terminals. J Neurosci Res 43:482-489.
58. Zimmer J, Geneser FA, 1987. Difference in monoamine oxidase B activity between C57 black and albino NMRI mouse strains may explain differential effects of the neurotoxin MPTP. Neurosci Lett 78:253-258.